BioCryst Current Assets vs Operating Expenses Analysis

BCRX Stock  USD 5.15  0.14  2.79%   
Trend analysis of BioCryst Pharmaceuticals balance sheet accounts such as Short Long Term Debt Total of 891.1 M, Other Current Liabilities of 108 M or Total Current Liabilities of 157.5 M provides information on BioCryst Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of BioCryst Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using BioCryst Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

About BioCryst Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of BioCryst Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. BioCryst Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of BioCryst Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which BioCryst currently owns. An asset can also be divided into two categories, current and non-current.

BioCryst Pharmaceuticals Balance Sheet Chart

BioCryst Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how BioCryst Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, BioCryst Pharmaceuticals' Liabilities And Stockholders Equity is fairly stable compared to the past year. Non Current Liabilities Total is likely to rise to about 863.6 M in 2024, despite the fact that Total Stockholder Equity is likely to grow to (432.8 M).

Total Assets

Total assets refers to the total amount of BioCryst Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in BioCryst Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on BioCryst Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of BioCryst Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.
Most indicators from BioCryst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 1.9 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 324.9 K in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses327.6M412.7M428.8M450.2M
Cost Of Revenue7.3M6.6M6.3M9.2M

BioCryst Pharmaceuticals fundamental ratios Correlations

0.930.90.87-0.630.790.71-0.940.910.750.060.990.950.940.150.520.950.811.0-0.39-0.310.930.640.93-0.66-0.3
0.930.880.81-0.390.860.91-0.920.790.51-0.010.890.860.990.230.720.990.850.93-0.4-0.260.850.820.84-0.54-0.2
0.90.880.95-0.550.90.77-0.940.820.510.260.880.910.87-0.080.580.90.870.88-0.18-0.220.90.760.9-0.64-0.34
0.870.810.95-0.540.890.7-0.950.870.490.190.860.950.81-0.010.610.850.820.860.01-0.140.960.750.96-0.72-0.41
-0.63-0.39-0.55-0.54-0.36-0.070.58-0.61-0.8-0.17-0.68-0.67-0.410.360.27-0.44-0.53-0.610.250.61-0.630.0-0.660.60.43
0.790.860.90.89-0.360.86-0.90.70.280.120.750.830.840.080.720.870.940.79-0.1-0.220.840.890.83-0.59-0.25
0.710.910.770.7-0.070.86-0.790.530.110.020.640.670.880.280.870.870.810.71-0.2-0.140.670.950.65-0.37-0.13
-0.94-0.92-0.94-0.950.58-0.9-0.79-0.88-0.57-0.06-0.92-0.98-0.92-0.11-0.63-0.95-0.88-0.940.140.28-0.97-0.77-0.970.670.43
0.910.790.820.87-0.610.70.53-0.880.77-0.050.920.930.810.040.450.830.630.92-0.22-0.050.930.50.93-0.64-0.34
0.750.510.510.49-0.80.280.11-0.570.77-0.070.810.670.55-0.03-0.10.560.380.76-0.54-0.350.63-0.020.65-0.52-0.2
0.06-0.010.260.19-0.170.120.02-0.06-0.05-0.070.080.04-0.06-0.13-0.09-0.030.16-0.020.2-0.190.00.060.010.0-0.39
0.990.890.880.86-0.680.750.64-0.920.920.810.080.950.910.090.440.920.770.99-0.41-0.320.920.560.92-0.68-0.31
0.950.860.910.95-0.670.830.67-0.980.930.670.040.950.880.050.520.910.810.95-0.14-0.260.990.660.99-0.72-0.44
0.940.990.870.81-0.410.840.88-0.920.810.55-0.060.910.880.260.711.00.840.95-0.41-0.260.860.790.85-0.53-0.2
0.150.23-0.08-0.010.360.080.28-0.110.04-0.03-0.130.090.050.260.460.220.060.16-0.07-0.060.040.240.030.25-0.04
0.520.720.580.610.270.720.87-0.630.45-0.1-0.090.440.520.710.460.710.530.530.070.250.550.920.52-0.22-0.1
0.950.990.90.85-0.440.870.87-0.950.830.56-0.030.920.911.00.220.710.850.96-0.36-0.250.890.80.89-0.57-0.23
0.810.850.870.82-0.530.940.81-0.880.630.380.160.770.810.840.060.530.850.8-0.25-0.520.810.780.81-0.59-0.24
1.00.930.880.86-0.610.790.71-0.940.920.76-0.020.990.950.950.160.530.960.8-0.41-0.30.930.630.93-0.66-0.27
-0.39-0.4-0.180.010.25-0.1-0.20.14-0.22-0.540.2-0.41-0.14-0.41-0.070.07-0.36-0.25-0.410.38-0.10.02-0.110.12-0.54
-0.31-0.26-0.22-0.140.61-0.22-0.140.28-0.05-0.35-0.19-0.32-0.26-0.26-0.060.25-0.25-0.52-0.30.38-0.22-0.03-0.250.260.12
0.930.850.90.96-0.630.840.67-0.970.930.630.00.920.990.860.040.550.890.810.93-0.1-0.220.681.0-0.76-0.4
0.640.820.760.750.00.890.95-0.770.5-0.020.060.560.660.790.240.920.80.780.630.02-0.030.680.66-0.44-0.16
0.930.840.90.96-0.660.830.65-0.970.930.650.010.920.990.850.030.520.890.810.93-0.11-0.251.00.66-0.77-0.4
-0.66-0.54-0.64-0.720.6-0.59-0.370.67-0.64-0.520.0-0.68-0.72-0.530.25-0.22-0.57-0.59-0.660.120.26-0.76-0.44-0.770.1
-0.3-0.2-0.34-0.410.43-0.25-0.130.43-0.34-0.2-0.39-0.31-0.44-0.2-0.04-0.1-0.23-0.24-0.27-0.540.12-0.4-0.16-0.40.1
Click cells to compare fundamentals

BioCryst Pharmaceuticals Account Relationship Matchups

BioCryst Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets175.3M334.7M588.2M550M517.0M542.8M
Short Long Term Debt Total84.7M124.7M593.2M741.5M848.7M891.1M
Other Current Liab36.3M55.6M72.7M87.6M102.9M108.0M
Total Current Liabilities92.3M105.7M103.7M105.5M150.0M157.5M
Total Stockholder Equity(840.6M)(1.0B)(1.2B)(1.5B)(455.5M)(432.8M)
Property Plant And Equipment Net7.3M7.1M8.7M15.4M21.0M22.0M
Net Debt(29.5M)(147.4M)88.8M436.7M736.3M773.1M
Retained Earnings(840.6M)(1.0B)(1.2B)(1.5B)(1.7B)(1.6B)
Accounts Payable14.0M18.7M27.8M14.4M20.9M21.9M
Cash114.2M272.1M504.4M304.8M112.4M65.7M
Non Current Assets Total10.9M10.9M22.0M33.5M21.0M24.6M
Cash And Short Term Investments136.2M300.4M514.4M442.4M390.8M410.3M
Common Stock Shares Outstanding103.2M115.6M167.3M179.1M192.2M201.8M
Liabilities And Stockholders Equity(703.6M)(669.5M)(512.4M)(610.0M)517.0M542.8M
Non Current Liabilities Total44.7M248.3M591.4M739.1M822.5M863.6M
Other Current Assets4.4M5.5M10.0M12.6M19.5M20.5M
Other Stockholder Equity(1.6M)(1.8M)(2.0M)(1.9M)1.2B1.3B
Total Liab137.0M354.0M695.1M844.6M972.5M1.0B
Property Plant And Equipment Gross7.3M7.1M8.7M25.0M19.1M20.1M
Total Current Assets164.3M323.8M566.1M516.5M496.0M520.8M
Accumulated Other Comprehensive Income39K3K177K26K1.3M1.4M
Short Term Debt40.0M31.2M1.8M2.4M26.2M27.5M
Non Currrent Assets Other3.6M3.8M6.5M(33.5M)12.0M7.6M
Common Stock Total Equity1.1M1.5M1.8M1.8M2.1M2.2M
Short Term Investments22.1M28.2M3.2M119.5M278.3M292.3M
Common Stock1.5M1.8M1.8M1.9M2.1M2.2M
Current Deferred Revenue2.1M150K1.4M1.2M1.1M1.0M
Property Plant Equipment7.3M7.1M15.2M15.4M17.7M18.6M
Other Assets2.0M978K588.2M550M632.5M664.1M
Net Receivables22.1M8.6M29.4M50.6M57.0M59.8M
Inventory1.6M7.0M15.8M27.5M28.7M30.1M
Net Tangible Assets82.9M109.3M(147.0M)(294.6M)(265.1M)(251.9M)
Long Term Debt41.3M119.7M585.5M733.3M811.3M851.8M
Retained Earnings Total Equity(732.0M)(840.6M)(1.0B)(1.2B)(1.1B)(1.0B)
Long Term Debt Total28.1M41.3M119.7M136.1M156.5M164.3M
Capital Surpluse780.4M877.3M1.0B1.1B1.3B745.7M

BioCryst Pharmaceuticals Investors Sentiment

The influence of BioCryst Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioCryst. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BioCryst Pharmaceuticals' public news can be used to forecast risks associated with an investment in BioCryst. The trend in average sentiment can be used to explain how an investor holding BioCryst can time the market purely based on public headlines and social activities around BioCryst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioCryst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioCryst Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioCryst Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioCryst Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioCryst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioCryst Pharmaceuticals' short interest history, or implied volatility extrapolated from BioCryst Pharmaceuticals options trading.

Pair Trading with BioCryst Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with BioCryst Stock

  0.61MBRX Moleculin Biotech Upward RallyPairCorr
  0.77MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against BioCryst Stock

  0.66DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.56MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.53MDWD Mediwound Financial Report 4th of June 2024 PairCorr
  0.44EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.43MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether BioCryst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioCryst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocryst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocryst Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for BioCryst Stock analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Directory
Find actively traded commodities issued by global exchanges
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Revenue Per Share
1.724
Quarterly Revenue Growth
0.174
Return On Assets
(0.12)
Return On Equity
(19.25)
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.